Sign In
Buy NVO
$47.41
-0.0100 (-0.0211%)
At Close: Jun 24, 2026
2 Biotech Stocks To Watch In September 2024
09:36pm, Tuesday, 10'th Sep 2024
Here are biotech stocks to check out this month.
Novo Nordisk experimental obesity pill has mild-to-moderate side effects in early trial
06:07pm, Tuesday, 10'th Sep 2024
Novo Nordisk's highly anticipated experimental weight-loss pill amycretin was safe and tolerable for patients in an early-stage trial, with mild-to-moderate side effects, the company said on Wednesday
Novo's older obesity drug is safe and effective for children, study finds
06:04pm, Tuesday, 10'th Sep 2024
Novo Nordisk's older weight-loss drug Saxenda helped children between the ages of 6 and under 12 reduce their body mass index by 7.4% in a 56-week trial, according to results presented at a medical me
Obesity drugs in kindergarten? Novo Nordisk GLP-1 drug works for kids as young as 6, study finds.
06:02pm, Tuesday, 10'th Sep 2024
Amid an ongoing debate over what role, if any, GLP-1 medications should play in treating children who are still in elementary school, researchers have concluded that a Novo Nordisk obesity drug may be
Is Novo Nordisk (NVO) a Buy as Wall Street Analysts Look Optimistic?
10:30am, Tuesday, 10'th Sep 2024
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employe
Novo Nordisk A/S (NVO) Is a Trending Stock: Facts to Know Before Betting on It
10:00am, Tuesday, 10'th Sep 2024
Novo Nordisk (NVO) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Novo Nordisk A/S - share repurchase programme
10:10am, Monday, 09'th Sep 2024
Bagsværd, Denmark, 9 September 2024 – On 7 August 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Cou
Novo Nordisk A/S - share repurchase programme
09:55am, Monday, 09'th Sep 2024
Novo Nordisk A/S – Share repurchase programme Bagsværd, Denmark, 9 September 2024 – On 7 August 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulatio
Eli Lilly's weekly insulin intensifies race with Novo Nordisk
08:47am, Thursday, 05'th Sep 2024
A pair of late-stage trials found that Eli Lilly's experimental once-weekly insulin can lower blood sugar as effectively as widely used daily insulins, the drugmaker said Thursday, intensifying the co
How Lilly, Novo Could Beat Tesla To The Trillion-Dollar Club; Plus, Nvidia's Battle With Microsoft, Apple
12:34pm, Wednesday, 04'th Sep 2024
Weight-loss drug kingpins Eli Lilly and Novo Nordisk could join the trillion-dollar company club before even Tesla, according to a report.
Ozempic shortages in EU will not affect all member states - Novo Nordisk
03:22am, Wednesday, 04'th Sep 2024
Intermittent shortages of diabetes drug Ozempic in the European Union that are expected to continue into the final quarter of 2024 because of strong demand will not affect all member states, the Danis
Weight-loss drugs could reduce COVID-related deaths: Study
01:56pm, Tuesday, 03'rd Sep 2024
A new study found that weekly injections of 2.4 mg of semaglutide could lower the risk of deaths related to COVID-19, marking another potential benefit of these blockbuster drugs.
Novo Nordisk's Says Ozempic Shortage Deteriorates. Why It's Good News For Eli Lilly.
07:09am, Tuesday, 03'rd Sep 2024
While Novo is struggling to keep up with demand for its obesity drugs, U.S. rival Eli Lilly sees supply restraints easing.
Novo Nordisk's Ozempic shortage expected to continue into Q4
11:49am, Monday, 02'nd Sep 2024
Novo Nordisk said the shortage of lower strengths of its diabetes drug Ozempic has deteriorated, with intermittent shortages for all strengths expected into the final quarter of 2024 due to increased
Novo to present at the Resources Rising Stars Gold Coast Investor Conference
08:36am, Monday, 02'nd Sep 2024
VANCOUVER, British Columbia, Sept. 02, 2024 (GLOBE NEWSWIRE) -- Novo Resources Corp. (Novo or the Company) (ASX: NVO) (TSX: NVO) (OTCQX: NSRPF) is pleased to advise that the Company's Executive Co-Cha
